TickerWorth Open the interactive view →

MetLife, Inc. (MET) — Valuation Snapshot

Updated Sep 3, 2026 · bank / insurer · relative-multiples view · descriptive, not a DCF, not advice

This is a bank / insurer / financial. A free-cash-flow DCF is structurally the wrong lens here (their debt and float are raw material, not financing), so we value it on relative multiples — price-to-book and price-to-earnings — instead.
Price
$96.42
Market cap
$61,272,682,496
52-week high
$100.93
52-week low
$67.33
Currency
USD
Exchange
NYSE

MetLife, Inc. (MET) is a bank, insurer or other financial, and a free-cash-flow discounted-cash-flow (DCF) model is structurally the wrong lens for it: for these businesses debt and float are raw material, not financing, so there is no meaningful 'free cash flow' to discount. Instead of a misleading intrinsic-value number, this page reads MET the way financials are actually valued — on relative multiples such as price-to-earnings and, above all, price-to-book — plus a plain description of where the stock trades. It is a descriptive snapshot, not a valuation, and not investment advice.

On the numbers we do have, MET trades at a recent price of $96.42, a market capitalisation of about $61,272,682,496, sitting 87% of the way up its 52-week range ($67.33–$100.93), on the NYSE.

The standard alternative to a DCF is relative valuation — comparing MET's trading multiples against its direct industry peers. Here that gives P/E of 18.1× (richer than the peer median of 11.1×); Fwd P/E of 8.8× (cheaper than the peer median of 11.7×); P/B of 2.2× (in line with the peer median of 2.1×); P/S of 0.8× (cheaper than the peer median of 1.5×); EV/EBITDA of 14.0× (richer than the peer median of 7.0×); Dividend yield of 2.5% (cheaper than the peer median of 1.4%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.

The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. MET shows a price-to-book (P/B) of 2.24 and book value of $43.03 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.

Finally, a price-based read — explicitly not a valuation. MET is in an up-trend (price above both its 50- and 200-day averages), trading -4.5% from its 52-week high. Over the past year the stock is +15.5%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.

To be exact about what this page is not: we are not saying the numbers for MET are unavailable. They are, and they are above. We are saying a discounted-cash-flow model is the wrong instrument for this kind of business, and publishing one anyway — because the inputs happen to exist — would be a precise answer to the wrong question. Refusing is the more useful answer, and it is the same rule we apply to every name in this category.

Relative valuation — MET vs peers

MultipleMETPeer median
P/E18.1×11.1×richer than
Fwd P/E8.8×11.7×cheaper than
P/B2.2×2.1×in line with
P/S0.8×1.5×cheaper than
EV/EBITDA14.0×7.0×richer than
Dividend yield2.5%1.4%cheaper than

Direct industry peers.

Asset / book-value view

Price / book (P/B)
2.24
Book value / share
$43.03

Price-to-book compares the market price to the accounting net-asset value per share. Most useful for asset-heavy businesses, banks and insurers.

Price-based snapshot

50-day avg
$93.62
200-day avg
$81.65
From 52-wk high
-4.5%
1-year momentum
+15.5%

Price-based, not a valuation. Moving-average trend and 52-week position describe where the stock has traded — they say nothing about fair value.

Compare MET with its peers

Companies people research alongside MET

Explore more

Most undervalued stocks (per our valuation) · All valued stocks · Interactive MET view

A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is an educational tool, not a licensed investment adviser. Figures are estimates derived from public market data and can be wrong, stale or incomplete.